




# PHARMACEUTICAL 2021

Tonix Pharmaceuticals Holding Corp.  
Rank 114 of 402





# PHARMACEUTICAL 2021

## Tonix Pharmaceuticals Holding Corp. Rank 114 of 402

The relative strengths and weaknesses of Tonix Pharmaceuticals Holding Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tonix Pharmaceuticals Holding Corp. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Tonix Pharmaceuticals Holding Corp. is the variable Research and Development, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 184%, being 137% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	87,989
Cost of Goods Sold	0
Intangible Assets	120
Liabilities, Current	9,819
Liabilities, Non-Current	716
Other Assets	1,503
Other Compr. Net Income	-16
Other Expenses	0
Other Liabilities	0
Other Net Income	48
Other Revenues	0
Property and Equipment	8,571
Research and Development	36,157
Selling, General and Administrative Expense	14,354

Output Variable	Value in 1000 USD
Assets	98,183
Liabilities	10,535
Expenses	50,511
Revenues	0
Stockholders Equity	87,648
Net Income	-50,463
Comprehensive Net Income	-50,471
Economic Capital Ratio	184%